Gerresheimer and Nelson Labs NV Announce E&L Partnership

Gerresheimer, a provider of drug delivery systems, and Nelson Labs, a provider of microbiological and analytical chemistry testing, announced a strategic partnership on Oct. 31, 2022. Under the partnership, which is designed to reduce risk and time-to-market for primary packaging solutions for injectables, Nelson Labs will conduct extractables and leachables testing, toxicological risk assessments, impurity identifications, and biocompatibility testing of injectable primary container closure systems or components for Gerresheimer.

“With this agreement, [we] will be able to offer an extended service package to our pharmaceutical and biotechnological customers for their new drug development and product life cycle management,” said Jen-Edouard Rabier, director, Business Development, Gx Biological Solutions, Gerresheimer, in a company press release. We are now able to provide our customers the best selection of primary packaging systems (vials, syringes, and cartridges) made of glass or cyclic olefin polymer (COP) without any concerns about compatibility, stability, or safety of the drug product.”

“I am extremely pleased that Gerresheimer and Nelson Labs have taken this very important step forward in joining our forces to provide customers with stellar testing and expert advice in container/closure qualification,” said Piet Christiaens, scientific director, Nelson Labs, in the release. “This partnership is designed to help the pharmaceutical industry take full advantage of our scientific leadership, unique Compounds Screener Database, personalized support, and other resources that will be offered through this alliance.”

Source: Gerresheimer